{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "REVOLUTION MED.  DL-,0001", "longName": "Revolution Medicines, Inc.", "messageBoardId": "finmb_283775412", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 23.2, "averageDailyVolume3Month": 5, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 9.300001, "fiftyTwoWeekLowChangePercent": 0.6690648, "fiftyTwoWeekRange": "13.9 - 27.6", "fiftyTwoWeekHighChange": -4.3999996, "fiftyTwoWeekHighChangePercent": -0.15942027, "fiftyTwoWeekLow": 13.9, "fiftyTwoWeekHigh": 27.6, "earningsTimestamp": 1683577800, "earningsTimestampStart": 1691405940, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.92, "epsForward": -2.72, "epsCurrentYear": -2.43, "priceEpsCurrentYear": -9.547325, "sharesOutstanding": 106313000, "bookValue": 8.958, "fiftyDayAverage": 21.176, "fiftyDayAverageChange": 2.0240002, "fiftyDayAverageChangePercent": 0.09557991, "twoHundredDayAverage": 21.636, "twoHundredDayAverageChange": 1.5640011, "twoHundredDayAverageChangePercent": 0.07228698, "marketCap": 2466461696, "forwardPE": -8.529412, "priceToBook": 2.5898638, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.1 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": 1.7543927, "regularMarketPrice": 23.2, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1581922800000, "priceHint": 2, "regularMarketChange": 0.40000153, "regularMarketTime": 1683871252, "regularMarketDayHigh": 23.2, "regularMarketDayRange": "23.2 - 23.2", "regularMarketDayLow": 23.2, "regularMarketVolume": 52, "regularMarketPreviousClose": 22.8, "bid": 23.4, "ask": 23.6, "symbol": "42Z.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 246, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith Ph.D.", "age": 60, "title": "CEO, Pres & Chairman", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": {"raw": 1053567, "fmt": "1.05M", "longFmt": "1,053,567"}, "exercisedValue": {"raw": 470619, "fmt": "470.62k", "longFmt": "470,619"}, "unexercisedValue": {"raw": 25079758, "fmt": "25.08M", "longFmt": "25,079,758"}}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": {"raw": 544800, "fmt": "544.8k", "longFmt": "544,800"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1620884, "fmt": "1.62M", "longFmt": "1,620,884"}}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 775600, "fmt": "775.6k", "longFmt": "775,600"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 7890083, "fmt": "7.89M", "longFmt": "7,890,083"}}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 61, "title": "Pres of R&D", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 779000, "fmt": "779k", "longFmt": "779,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4615888, "fmt": "4.62M", "longFmt": "4,615,888"}}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 51, "title": "Exec. VP of Clinical Devel.", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 604100, "fmt": "604.1k", "longFmt": "604,100"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4985429, "fmt": "4.99M", "longFmt": "4,985,429"}}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 41, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David S. Arrington", "title": "Sr. VP of Investor Relations & Corp. Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 2, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}